Weiss Ratings Reaffirms Sell (E+) Rating for 10x Genomics (NASDAQ:TXG)

10x Genomics (NASDAQ:TXG)‘s stock had its “sell (e+)” rating reaffirmed by equities research analysts at Weiss Ratings in a research report issued on Saturday,Weiss Ratings reports.

TXG has been the topic of several other research reports. Deutsche Bank Aktiengesellschaft set a $14.00 price objective on 10x Genomics and gave the stock a “hold” rating in a report on Friday, August 8th. UBS Group boosted their price target on shares of 10x Genomics from $12.00 to $13.00 and gave the company a “neutral” rating in a report on Friday, August 8th. Bank of America raised their price objective on shares of 10x Genomics from $12.00 to $13.00 and gave the stock a “neutral” rating in a report on Thursday, June 26th. Wall Street Zen lowered shares of 10x Genomics from a “buy” rating to a “hold” rating in a research report on Saturday. Finally, Canaccord Genuity Group set a $16.00 price target on shares of 10x Genomics in a research report on Monday, August 11th. Six equities research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $13.65.

10x Genomics Price Performance

NASDAQ TXG opened at $13.35 on Friday. The firm has a market capitalization of $1.66 billion, a price-to-earnings ratio of -19.07 and a beta of 2.00. The company’s fifty day moving average is $13.24 and its two-hundred day moving average is $10.83. 10x Genomics has a 52-week low of $6.78 and a 52-week high of $24.38.

10x Genomics (NASDAQ:TXG) last announced its quarterly earnings data on Thursday, August 7th. The company reported $0.28 EPS for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.63. 10x Genomics had a negative net margin of 13.13% and a negative return on equity of 12.88%. The business had revenue of $172.91 million during the quarter, compared to analyst estimates of $139.36 million. During the same quarter in the prior year, the business earned ($0.32) earnings per share. The firm’s revenue for the quarter was up 12.9% on a year-over-year basis. 10x Genomics has set its Q3 2025 guidance at EPS. As a group, sell-side analysts expect that 10x Genomics will post -1.43 earnings per share for the current fiscal year.

Insider Activity at 10x Genomics

In other 10x Genomics news, CFO Adam Taich sold 22,315 shares of the business’s stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $13.79, for a total value of $307,723.85. Following the transaction, the chief financial officer directly owned 309,273 shares in the company, valued at $4,264,874.67. The trade was a 6.73% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Benjamin J. Hindson sold 7,486 shares of the company’s stock in a transaction dated Friday, August 22nd. The stock was sold at an average price of $13.79, for a total transaction of $103,231.94. Following the sale, the insider directly owned 440,888 shares in the company, valued at $6,079,845.52. This represents a 1.67% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 39,149 shares of company stock valued at $539,865 in the last ninety days. Insiders own 10.03% of the company’s stock.

Hedge Funds Weigh In On 10x Genomics

A number of institutional investors and hedge funds have recently bought and sold shares of TXG. GF Fund Management CO. LTD. bought a new stake in shares of 10x Genomics during the fourth quarter worth $32,000. Allworth Financial LP grew its holdings in 10x Genomics by 150.4% during the 2nd quarter. Allworth Financial LP now owns 2,271 shares of the company’s stock worth $26,000 after acquiring an additional 1,364 shares during the last quarter. GAMMA Investing LLC increased its position in 10x Genomics by 81.8% in the 1st quarter. GAMMA Investing LLC now owns 3,586 shares of the company’s stock valued at $31,000 after acquiring an additional 1,614 shares in the last quarter. True Wealth Design LLC raised its stake in shares of 10x Genomics by 1,552.5% in the second quarter. True Wealth Design LLC now owns 3,586 shares of the company’s stock worth $42,000 after acquiring an additional 3,369 shares during the last quarter. Finally, Signaturefd LLC lifted its position in shares of 10x Genomics by 134.3% during the first quarter. Signaturefd LLC now owns 4,203 shares of the company’s stock worth $37,000 after purchasing an additional 2,409 shares in the last quarter. Institutional investors and hedge funds own 84.68% of the company’s stock.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.